Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening
NCT ID: NCT07155252
Last Updated: 2025-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2025-08-26
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes
NCT05777330
OGTT at Home Using CGM vs at the Clinic
NCT06862128
Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)
NCT00333853
Oral Glucose Tolerance Testing After Gestational Diabetes
NCT02082301
Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial
NCT01788527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single islet autoantibody
Participants with single islet autoantibody
GTT@Home
self-administered fingerstick based glucose tolerance test
2 or more positive islet antibodies
Participants with 2 or more positive islet antibodies who are in (Stage 1) or (Stage 2) without dysglycemia
GTT@Home
self-administered fingerstick based glucose tolerance test
Recently diagnosed with diabetes
Participants meeting the diagnostic criteria for diabetes (stage 3 T1D) within 100 days from the diagnosis
GTT@Home
self-administered fingerstick based glucose tolerance test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GTT@Home
self-administered fingerstick based glucose tolerance test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days.
* Documentation of the presence at least 1 islet autoantibody
* If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old.
* Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study,
* Ability to give consent/assent
* Able to understand written and spoken English
Exclusion Criteria
* Participants on sodium glucose cotransporter inhibitors (SGLTi).
* Donated blood in the past 8 weeks.
8 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Breakthrough T1D
OTHER
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfonso Galderisi, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University Pediatric and Adult Diabetes Clinic
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2000040441
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.